Substance / Medication

Hydralazine

SNOMED 387125005 UMLS C0020223

Overview

Active Ingredient

hydralazine

RxNorm CUI

5470

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Malignant hypertension

Pulmonary hypertension

Heart failure

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Creatinine

LOINC 2160-0

secondary

Potassium

LOINC 2823-3

secondary

Natriuretic peptide.B

LOINC 30934-4

primary

Natriuretic peptide.B prohormone N-Terminal

LOINC 33762-6

primary

Clinical Trials

4 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

NCT06218199Phase 4Recruiting80 enrolled

Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus

NCT02046395Phase 4Completed28 enrolled

Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD

NCT02228408Phase 4Completed17 enrolled

Black Education and Treatment of Hypertension (BEAT HTN)

NCT00661895Phase 4Completed99 enrolled

View all 4 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Efficacy and Safety of Nifedipine Compared to Intravenous Hydralazine for Severe Hypertensive Disorders in Pregnancy: A Systematic Review and Meta-Analysis of Randmomized Controlled Trials.

Govindasamy Vaisnavy, Kamel Mohammed Amer, Volucke Gabriele et al. · Med Sci (Basel) · 2025

PMID: 40700120Meta-AnalysisFull text (PMC)

Comparative efficacy and safety between intravenous labetalol and intravenous hydralazine for hypertensive disorders in pregnancy: A systematic review and meta-analysis of 19 randomized controlled trials.

Gonçalves Ocílio Ribeiro, Bendaham Lucas Cael Azevedo Ramos, Simoni Gabriel Henrique et al. · Eur J Obstet Gynecol Reprod Biol · 2024

PMID: 39522185Meta-Analysis

Safety and efficacy of intravenous hydralazine and labetalol for the treatment of asymptomatic hypertension in hospitalised patients: A systematic review.

Cawoski Jocelyn R, DeBiasio Katie A, Donnachie Scott W et al. · Int J Clin Pract · 2021

PMID: 33400322Meta-Analysis

The flipside of hydralazine in pregnancy: A systematic review and meta-analysis.

Antza Christina, Dimou Chrisa, Doundoulakis Ioannis et al. · Pregnancy Hypertens · 2020

PMID: 32044579Meta-Analysis

Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review.

Farag Mohamed, Mabote Thato, Shoaib Ahmad et al. · Int J Cardiol · 2015

PMID: 26073215Meta-Analysis

Hydralazine in infants with persistent hypoxemic respiratory failure.

Kawaguchi Atsushi, Isayama Tetsuya, Mori Rintaro et al. · Cochrane Database Syst Rev · 2013

PMID: 23450605Meta-AnalysisFull text (PMC)

Hydralazine for essential hypertension.

Kandler Michael R, Mah Greg T, Tejani Aaron M et al. · Cochrane Database Syst Rev · 2011

PMID: 22071816Meta-Analysis

Hydralazine for essential hypertension.

Kandler Michael R, Mah Greg T, Tejani Aaron M et al. · Cochrane Database Syst Rev · 2010

PMID: 20687078Meta-Analysis

Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis.

Magee Laura A, Cham Chris, Waterman Elizabeth J et al. · BMJ · 2003

PMID: 14576246Meta-AnalysisFull text (PMC)

Hydralazine combined with conventional therapy improved outcomes in severe systolic dysfunction and mitral regurgitation.

Hsiao Shih-Hung, Hsiao Chao-Sheng, Shiau Jau-Wen et al. · ESC Heart Fail · 2024

PMID: 37897153RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Internal Medicine Physician

Internal Medicine

NUCC 207R00000X

Cardiovascular Disease Physician

Internal Medicine — Cardiovascular Disease

NUCC 207RC0000X

Find a Provider

Health Goals

Goals connected through associated conditions

Improve Cardiovascular Fitness

Quick Facts

Type: Substance / Medication
Fully Specified Name: Hydralazine (substance)
SNOMED CT: 387125005
UMLS CUI: C0020223
RxNorm CUI: 5470

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.